Loading…
Loading…


BATM Advanced Communications Ltd (LSE:BVC), a London-listed technology innovator, is making headlines with progress in its diagnostics division. Its NATlab platform, developed by associate company ADOR Diagnostics, has begun pre-clinical validation at Rome's Lazzaro Spallanzani National Institute for Infectious Diseases.

BATM Advanced Communications Ltd (LSE:BVC) has announced a major step forward in the development of its NATlab diagnostic platform, which has begun pre-clinical validation at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome. This follows successful trials in Israel, confirming the system's effectiveness in identifying infectious diseases quickly and accurately.